Company intelligence / Profile preview

Viska Solutions

Cambridge, Massachusetts, United Statesjustdial.com ↗

Ownership: Private
Development stage: Commercial

Overview

Viska Bio is developing a proprietary immunotherapy platform using patented fusion proteins to induce immunogenic cell death in targeted unwanted cells such as cancer. The company’s lead program is in preclinical development, with efforts focused on advancing toward IND-enabling studies. No clinical results have been reported yet

Therapeutic areas: OncologyInfectious DiseasesOther
Modalities: Fusion proteinBiologic
Industry: Biotech

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed; maintains partnerships with contract research organizations and external research collaborators

Beyond the preview

Go deeper on Viska Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viska Solutions.

Explore the full profile